Takeda Pharmaceutical Co Ltd

{ "date": [ "202703", "202803", "202903", "203003" ], "revenue_estimate": [ 28828.26, 29753.91, 30563.08, 29757.41 ], "ebit_estimate": [ 3160.17, 3881.59, 5101.16, null ], "ebitda_estimate": [ 7331.17, 8016.98, 8766.77, null ], "net_income_estimate": [ 4825.85, 4976.93, 5448.34, 5992.3 ], "per_share_eps_estimate": [ 0.69, 0.46, null, null ], "eps_nri_estimate": [ 3, 3.14, 3.41, 3.77 ], "dividend_estimate": [ 0.63, 0.67, 0.7, null ], "book_value_per_share_estimate": [ 28.47, 28.49, 29.11, null ], "pretax_income_estimate": [ 2177.79, 2725.88, 4087.49, null ], "operating_cash_flow_per_share_estimate": [ 577.39, 559.57, null, null ], "roa_estimate": [ 2.77, 4.17, 5.47, null ], "roe_estimate": [ 6.27, 11.15, 12.31, null ], "gross_margin_estimate": [ 65.4, 66.9, 68, 69 ], "operating_cash_flow_estimate": [ 1823750.35, 1767450.1, null, null ], "pettm_estimate": [ 24, 35.84, null, null ], "long_term_growth_rate_mean": 41.14, "long_term_revenue_growth_rate_mean": "2.34", "future_per_share_eps_estimate_growth": 29.12, "future_eps_nri_estimate_growth": 41.14, "future_revenue_estimate_growth": 2.34, "future_ebit_estimate_growth": 380.17, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": 2.3, "future_net_income_estimate_growth": 31.36, "future_pretax_income_estimate_growth": 27.49, "future_book_value_per_share_estimate_growth": -1.55, "future_roa_estimate_growth": 41.69, "future_roe_estimate_growth": 34.91, "future_gross_margin_estimate_growth": 6.2, "future_operating_cash_flow_per_share_estimate_growth": 6.18 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 7240.47, 7264.73, 7331.11, 6929.24, 7223.25, 7321.72, 7534.36, 7204.59 ], "ebit_estimate": [ 601.56, 623.88, 729.15, 662.09, 921.95, 944.2, 1056.91, 944.52 ], "ebitda_estimate": [ 1755.14, 1756.28, 1841.13, 1878.46, 1959.3, 1970.45, 2072.47, 2014.75 ], "net_income_estimate": [ 1400.9, 1334.06, 1220.38, 870.5, 1355.7, 1333.12, 1267.16, 1017.86 ], "per_share_eps_estimate": [ null, null, null, null, null, null, null, null ], "eps_nri_estimate": [ 0.79, 0.81, 0.77, 0.64, 0.86, 0.84, 0.8, 0.64 ], "dividend_estimate": [ null, 0.31, null, 0.33, null, 0.31, null, 0.36 ], "book_value_per_share_estimate": [ 28.69, 28.84, 28.41, 28.47, 28.1, 28.51, 28.26, 28.49 ], "pretax_income_estimate": [ 333.46, 355.79, 461.06, 394, 636.53, 658.77, 771.49, 659.09 ], "operating_cash_flow_per_share_estimate": [ 142.9, 142.87, 147.07, 144.56, 137.74, 138.48, 143.57, 139.78 ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 66.3, 66, 66, 63, 67.4, 67.5, 66.4, 66.2 ], "operating_cash_flow_estimate": [ 451367.95, 451262.22, 464521.62, 456598.56, 435065.42, 437398.52, 453490.2, 441495.97 ], "pettm_estimate": [ null, null, null, null, null, null, null, null ], "long_term_growth_rate_mean": 41.14, "long_term_revenue_growth_rate_mean": "2.34", "future_per_share_eps_estimate_growth": 29.12, "future_eps_nri_estimate_growth": 41.14, "future_revenue_estimate_growth": 2.34, "future_ebit_estimate_growth": 380.17, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": 2.3, "future_net_income_estimate_growth": 31.36, "future_pretax_income_estimate_growth": 27.49, "future_book_value_per_share_estimate_growth": -1.55, "future_roa_estimate_growth": 41.69, "future_roe_estimate_growth": 34.91, "future_gross_margin_estimate_growth": 6.2, "future_operating_cash_flow_per_share_estimate_growth": 6.18 }